Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23320065 | 0.71 | HPGD (0.48) | ALDH1A1HPGDTSHRSMN1; SMN2NPSR1 | |
| SCHEMBL2214489 | 0.71 | NOTUM (0.70) | ALDH1A1HPGDTSHRSMN1; SMN2NPSR1 | |
| SCHEMBL5922348 | 0.70 | LMNA (0.69) | ALDH1A1HPGDTSHRSMN1; SMN2NPSR1 | |
| SCHEMBL2588443 | 0.70 | ALDH1A1 (0.72) | ALDH1A1HPGDTSHRSMN1; SMN2KMT2A | |
| SCHEMBL2213963 | 0.70 | NPSR1 (0.70) | ALDH1A1HPGDTSHRSMN1; SMN2NPSR1 | |
| SCHEMBL4432239 | 0.69 | ALDH1A1 (0.50) | ALDH1A1HPGDTSHRNPSR1KMT2A | |
| SCHEMBL10414225 | 0.69 | TSHR (0.60) | ALDH1A1HPGDTSHRSMN1; SMN2NPSR1 | |
| SCHEMBL4574192 | 0.69 | ALDH1A1 (0.67) | ALDH1A1HPGDTSHRSMN1; SMN2NPSR1 | |
| SCHEMBL28369636 | 0.68 | TDP1 (0.49) | ALDH1A1HPGDTSHRSMN1; SMN2KMT2A | |
| SCHEMBL50441 | 0.68 | ALDH1A1 (0.89) | ALDH1A1HPGDTSHRNPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222274-B2 | Pyrrole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-07-17 | — | — | US | disclosed |
| EP-1988075-B1 | PYRROLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-20090036421-A1 | Pyrrole Derivative or Salt Thereof | ASTELLAS PHARMA INC (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1988075-A1 | PYRROLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036421-A1 | Pyrrole Derivative or Salt Thereof | HTR7, HTR2B, SSTR5 | ALDH1A1 4209/4885HPGD 1353/4885TSHR 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.